Cingulate Inc. Establishes $100M At-The-Market Offering and Secures Shareholder Approval for Prior Issuances
CING has more than doubled off its 52-week low of $3.2.
Summary
Cingulate Inc. launched a new $100 million At-The-Market offering to raise capital, a highly dilutive move for a company facing a going concern, while also securing shareholder approval for prior stock issuances.
Key Events · Financing and Capital Events · CING
-
Establishes $100M At-The-Market (ATM) Offering
Cingulate Inc. entered into an ATM Sales Agreement to sell up to $100,000,000 of common stock. This program allows the company to sell shares into the market over time, providing a significant source of capital but also representing substantial potential dilution for existing shareholders, given the company's market capitalization.
-
Shareholders Approve Prior Stock Issuances
At a Special Meeting, stockholders approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or exercise of warrants, as per a securities purchase agreement dated January 27, 2026. This vote was necessary for Nasdaq compliance to enable the company to complete a previously announced financing.
Analysis · CING · Life Sciences
Cingulate Inc. has established a new At-The-Market (ATM) Sales Agreement, enabling it to sell up to $100 million of common stock from time to time. This represents a substantial capital raise, significantly exceeding the company's current market capitalization, and indicates a critical need for funding. The ATM program utilizes the universal shelf registration statement (File No. 333-292680) that was recently amended on March 23, 2026. This aggressive financing effort follows the company's recent 10-K filing on March 18, 2026, which disclosed a going concern warning and a short cash runway, making this ATM a vital, albeit highly dilutive, mechanism for extending its operational runway. Additionally, shareholders approved the issuance of common stock related to a prior financing agreement from January 27, 2026, which involved Series A Convertible Preferred Stock and warrants. This approval is a necessary compliance step to enable the company to fulfill its obligations under that previous agreement.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 39.2% of the 344 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CING was trading at $6.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78M. The 52-week trading range was $3.20 to $11.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.